Rubyanne Deveras, MD
Hematology & Oncology · Washington, DCNPI 1306844360
Payments from drug & device makers
Across 438 payments — averaging $336.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$99K
- Amgen$38K
- Novo Nordisk AS$2K
- Novartis$1K
- AstraZeneca$870
- E.r. Squibb & Sons, L.L.C.$644
- plus $6K from 37 others
What the payments were for
- Travel & lodging$1,48513%
- Food & beverage$9,74486%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 20 | $98,988 |
| Amgen | 25 | $37,582 |
| Novo Nordisk AS | 4 | $1,750 |
| Novartis | 61 | $1,386 |
| AstraZeneca | 42 | $870 |
| E.r. Squibb & Sons, L.L.C. | 21 | $644 |
| Merck | 24 | $586 |
| Daiichi Sankyo Inc. | 29 | $580 |
| Seagen Inc. | 21 | $464 |
| Lilly USA, LLC | 23 | $454 |
| Incyte Corporation | 15 | $322 |
| Penumbra, Inc. | 2 | $303 |
| Pfizer | 15 | $285 |
| Johnson & Johnson | 10 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $273 |
| Genentech USA, Inc. | 15 | $269 |
| Gilead | 12 | $255 |
| Novo Nordisk | 5 | $205 |
| Eisai Inc. | 9 | $185 |
| Caris MPI, Inc. | 4 | $182 |
| Astellas Pharma US Inc | 3 | $173 |
| Stemline Therapeutics Inc. | 4 | $172 |
| Bayer | 4 | $164 |
| ADC Therapeutics America, Inc. | 7 | $157 |
| Exelixis Inc. | 8 | $156 |
| Sanofi | 5 | $143 |
| Taiho Oncology, Inc. | 7 | $130 |
| Puma Biotechnology, Inc. | 7 | $115 |
| AbbVie | 4 | $85 |
| Foundation Medicine, Inc. | 2 | $57 |
| CSL Behring | 2 | $52 |
| EMD Serono, Inc. | 2 | $33 |
| Tempus AI, Inc | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| GSK | 1 | $25 |
| Dova Pharmaceuticals | 1 | $22 |
| Geron Corporation | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| CTI Biopharma Corp. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,527 in reported general payments places this provider in the 60th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 19 | $406,147 |
| JakafiRuxolitinib Phosphate | 11 | $193,621 |
| TagrissoOsimertinib Mesylate | 11 | $175,528 |
| KeytrudaPembrolizumab | 11 | $126,465 |
| PromactaEltrombopag Olamine | 14 | $100,760 |
| EliquisApixaban | 83 | $85,489 |
| Anastrozole | 265 | $8,930 |
| XareltoRivaroxaban | 14 | $8,898 |
| Deferasirox | 13 | $3,125 |
| Exemestane | 36 | $2,926 |
| Ondansetron Hcl | 39 | $2,262 |
| Tamoxifen Citrate | 40 | $1,616 |
| Letrozole | 29 | $922 |
| Lorazepam | 69 | $858 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $98,988 | $406,14719 claims |
| Incyte CorporationJakafi | $322 | $193,62111 claims |
| AstraZenecaTagrisso | $870 | $175,52811 claims |
| MerckKeytruda | $586 | $126,46511 claims |
| NovartisPromacta | $1,386 | $100,76014 claims |
| PfizerEliquis | $285 | $85,48983 claims |
| Johnson & JohnsonXarelto | $276 | $8,89814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Pavani ChalasaniWashington$10.3M
- Chul KimWashington$8.4M
- Vered StearnsWashington$7.8M
- Benjamin WeinbergWashington$7.3M
- Claudine IsaacsWashington$5.3M
- Julie BaumanWashington$3.4M
- Catherine BroomeWashington$2.9M
- Suthee RapisuwonWashington$1.9M
- Julie CollinsWashington$1.8M
- Ami ChitaliaWashington$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.